Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

Abstract

Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD). All stages of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate prevalence data are lacking. Thus we sought to determine the prevalence of CKD globally, by stage, geographical location, gender and age. A systematic review and meta-analysis of observational studies estimating CKD prevalence in general populations was conducted through literature searches in 8 databases. We assessed pooled data using a random effects model. Of 5,842 potential articles, 100 studies of diverse quality were included, comprising 6,908,440 patients. Global mean(95%CI) CKD prevalence of 5 stages 13·4%(11·7–15·1%), and stages 3–5 was 10·6%(9·2–12·2%). Weighting by study quality did not affect prevalence estimates. CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3·5% (2·8–4·2%); Stage-2 (eGFR 60–89+ACR>30): 3·9% (2·7–5·3%); Stage-3 (eGFR 30–59): 7·6% (6·4–8·9%); Stage-4 = (eGFR 29–15): 0·4% (0·3–0·5%); and Stage-5 (eGFR<15): 0·1% (0·1–0·1%). CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3. Future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.

Self-Management Program for People with Chronic Kidney Disease in Vietnam: A Pragmatic Randomised Controlled Trial

“…The global prevalence of CKD in all adults is estimated at between 10% to 16% (Dienemann et al, 2016), with the majority of people in stages 3-5 (10.6%) (Hill et al, 2016). The estimated prevalence of CKD varies considerably and this may be due to whether the disease has been diagnosed and also the methods for collecting national data for reporting in registries.…”

Wearable sensors: can they benefit patients with chronic kidney disease?

“…CKD is a costly and rapidly growing worldwide public health problem. A recent thorough meta-study revealed a consistent estimated global CKD prevalence (counting all five CKD-stages) between 11% and 13%, from which the majority was at CKD-stage 3 (6.4-8.9%) [1].…”

Nano-sized carriers in gene therapy for renal fibrosisin vivo

“…A recent meta-analysis reported that the global prevalence of CKD is estimated as 13.4% in general populations [2]. In the pathology of CKD, tubulointerstitial fibrosis, called renal fibrosis, is the final common pathway leading to end-stage renal disease regardless of initial nephropathies [3,4].…”